2.1
Pembrolizumab (Keytruda, Merck Sharp & Dohme) is indicated for 'the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy'.
2 Information about pembrolizumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
Price
2.3
The list price is £2,630 per 100‑mg vial (excluding VAT; BNF online, accessed October 2024).
2.4
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.